<DOC>
	<DOC>NCT01501331</DOC>
	<brief_summary>The Boston Scientific Energen family is capable of measuring the respiratory rate trend (RRT) on a daily basis and transmission of data via the Remote Monitoring technology. This may result in early detection of imminent decompensation at a presymptomatic stage. The study will assess the respiratory trends correlation with clinically relevant heart failure events.</brief_summary>
	<brief_title>Multiparametric Heart Failure Evaluation in Internal Cardioverter Defibrillators (ICD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patient eligible for 1, 2 or 3chamber ICD implantation according to current guidelines or patient already implanted within the past 45 days with a Energen device or successor Able to provide written informed consent Life expectancy &lt;12 months Anticipated noncompliance with the followup scheme Moderate to severe Chronic Obstructive Pulmonary Disease Primary pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Cardiac Resynchronization Therapy</keyword>
	<keyword>Internal Cardioverter Defibrillators</keyword>
</DOC>